Latest Ratios: P/E Ratio 22.5x · EV/EBITDA 14.2x · ROE 9.8%. (1997–2026 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $107.6B | $107.3B | $109.3B | $106.7B | $121.2B | $141.0B | $177.3B | $131.9B | $120.6B | $109.6B | $115.6B |
| Enterprise Value | $133.6B | $133.3B | $135.6B | $130.5B | $144.0B | $161.4B | $200.1B | $152.6B | $141.5B | $131.7B | $144.0B |
| P/E Ratio → | 22.47 | 22.34 | 23.48 | 29.07 | 32.25 | 27.98 | 49.22 | 27.58 | 26.04 | 35.30 | 28.75 |
| P/S Ratio | 2.96 | 2.95 | 3.26 | 3.30 | 3.88 | 4.45 | 5.89 | 4.56 | 3.95 | 3.66 | 3.89 |
| P/B Ratio | 2.16 | 2.14 | 2.27 | 2.12 | 2.35 | 2.68 | 3.44 | 2.59 | 2.40 | 2.16 | 2.29 |
| P/FCF | 19.84 | 19.78 | 21.09 | 20.53 | 26.47 | 23.59 | 36.29 | 21.91 | 20.53 | 30.32 | 20.55 |
| P/OCF | 14.68 | 14.64 | 15.52 | 15.73 | 20.07 | 19.20 | 28.41 | 18.23 | 17.21 | 23.41 | 16.80 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.67 | 4.04 | 4.03 | 4.61 | 5.09 | 6.64 | 5.28 | 4.63 | 4.40 | 4.85 |
| EV / EBITDA | 14.18 | 14.15 | 15.38 | 16.75 | 17.60 | 19.08 | 27.84 | 20.47 | 15.85 | 14.19 | 17.35 |
| EV / EBIT | 20.66 | 19.46 | 21.34 | 23.48 | 24.01 | 26.60 | 41.51 | 29.64 | 21.30 | 19.31 | 25.29 |
| EV / FCF | — | 24.57 | 26.16 | 25.09 | 31.45 | 27.00 | 40.95 | 25.34 | 24.09 | 36.43 | 25.60 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 65.0% | 65.0% | 65.3% | 65.3% | 65.7% | 68.0% | 65.2% | 67.4% | 70.0% | 69.7% | 68.7% |
| Operating Margin | 17.8% | 17.8% | 17.8% | 15.9% | 17.6% | 18.2% | 14.9% | 16.6% | 20.5% | 22.2% | 18.1% |
| Net Profit Margin | 13.2% | 13.2% | 13.9% | 11.4% | 12.0% | 15.9% | 12.0% | 16.6% | 15.2% | 10.4% | 13.6% |
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 9.8% | 9.8% | 9.4% | 7.2% | 7.2% | 9.7% | 7.0% | 9.5% | 9.2% | 6.1% | 7.9% |
| ROA | 5.2% | 5.2% | 5.1% | 4.1% | 4.1% | 5.5% | 3.9% | 5.3% | 5.1% | 3.2% | 4.0% |
| ROIC | 6.4% | 6.4% | 6.0% | 5.2% | 5.6% | 5.8% | 4.6% | 5.0% | 6.5% | 6.6% | 5.1% |
| ROCE | 8.1% | 8.1% | 7.5% | 6.4% | 6.8% | 7.1% | 5.4% | 5.9% | 7.7% | 8.0% | 6.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.56 | 0.56 | 0.59 | 0.50 | 0.47 | 0.46 | 0.51 | 0.49 | 0.50 | 0.51 | 0.66 |
| Debt / EBITDA | 2.97 | 2.97 | 3.23 | 3.21 | 2.98 | 2.85 | 3.67 | 3.33 | 2.84 | 2.77 | 4.02 |
| Net Debt / Equity | — | 0.52 | 0.54 | 0.47 | 0.44 | 0.39 | 0.44 | 0.41 | 0.42 | 0.43 | 0.56 |
| Net Debt / EBITDA | 2.76 | 2.76 | 2.98 | 3.05 | 2.79 | 2.41 | 3.17 | 2.77 | 2.34 | 2.38 | 3.43 |
| Debt / FCF | — | 4.79 | 5.07 | 4.57 | 4.98 | 3.41 | 4.67 | 3.43 | 3.56 | 6.11 | 5.05 |
| Interest Coverage | 9.58 | 9.58 | 8.72 | 7.73 | 9.43 | 10.98 | 5.21 | 4.71 | 4.60 | 5.95 | 5.21 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.13 | 2.13 | 1.85 | 2.03 | 2.39 | 1.86 | 2.65 | 2.13 | 2.59 | 2.28 | 1.74 |
| Quick Ratio | 1.62 | 1.62 | 1.42 | 1.55 | 1.81 | 1.49 | 2.14 | 1.72 | 2.15 | 1.92 | 1.51 |
| Cash Ratio | 0.79 | 0.79 | 0.70 | 0.74 | 0.88 | 0.85 | 1.27 | 1.06 | 1.16 | 1.11 | 0.96 |
| Asset Turnover | — | 0.39 | 0.37 | 0.36 | 0.34 | 0.35 | 0.32 | 0.32 | 0.34 | 0.33 | 0.30 |
| Inventory Turnover | 2.14 | 2.14 | 2.12 | 2.15 | 2.03 | 2.20 | 2.43 | 2.23 | 2.44 | 2.53 | 2.78 |
| Days Sales Outstanding | — | 66.68 | 70.91 | 69.11 | 70.11 | 63.94 | 66.20 | 58.64 | 74.32 | 72.96 | 68.69 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 3.4% | 3.4% | 3.3% | 3.4% | 3.0% | 2.4% | 1.8% | 2.2% | 2.2% | 2.3% | 2.1% |
| Payout Ratio | 75.8% | 75.8% | 77.0% | 99.7% | 96.2% | 67.1% | 86.5% | 60.4% | 58.2% | 80.3% | 59.0% |
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 4.4% | 4.5% | 4.3% | 3.4% | 3.1% | 3.6% | 2.0% | 3.6% | 3.8% | 2.8% | 3.5% |
| FCF Yield | 5.0% | 5.1% | 4.7% | 4.9% | 3.8% | 4.2% | 2.8% | 4.6% | 4.9% | 3.3% | 4.9% |
| Buyback Yield | 1.0% | 1.0% | 3.0% | 2.0% | 0.5% | 1.8% | 0.4% | 1.0% | 2.4% | 2.0% | 3.1% |
| Total Shareholder Yield | 4.3% | 4.4% | 6.2% | 5.4% | 3.5% | 4.2% | 2.1% | 3.2% | 4.6% | 4.3% | 5.1% |
| Shares Outstanding | — | $1.3B | $1.3B | $1.3B | $1.3B | $1.4B | $1.4B | $1.4B | $1.4B | $1.4B | $1.4B |
Portfolio integration and competition
Based on current market data, Medtronic trades at a forward P/E of 13.59, which appears to discount the firm relative to peers like Stryker and Abbott, potentially reflecting investor skepticism regarding the long-term success of the company's ongoing portfolio optimization and its ability to sustain recent growth.
The valuation gap between Medtronic and higher-growth pure-play competitors suggests that the market is applying a conglomerate discount to its diverse business units. While the forward P/E is attractive, investors should monitor whether this multiple expansion is constrained by the historical volatility in operating margins rather than just a lack of growth.
As reported in recent financial statements, Medtronic's ROIC has hovered between 1.1% and 1.7% over the last ten quarters, a level that appears structurally low for a medical device leader and suggests that the company's massive asset base, heavily weighted toward goodwill, is not yet generating optimal returns.
The persistent gap between invested capital and returns indicates that past acquisitions may be diluting the company's overall capital efficiency. Management's focus on portfolio optimization warrants further investigation to determine if divestitures of lower-growth assets will eventually catalyze a meaningful improvement in these return metrics.
According to quarterly filings, Medtronic's cash conversion cycle has fluctuated wildly, reaching as high as 187 days in 2024Q3 before compressing to 30 days in 2026Q4, which suggests significant instability in inventory management and potential challenges in aligning supply chain throughput with actual hospital demand.
The extreme variance in the CCC metric implies that the company may be struggling with inventory bloat or inconsistent accounts receivable collection cycles. This volatility complicates the assessment of operational efficiency and suggests that the firm's working capital management is currently a source of friction rather than a competitive advantage.
Based on the 2026Q4 current ratio of 2.13, Medtronic maintains a robust liquidity position that appears sufficient to withstand short-term market shocks, as reported in recent financial statements, ensuring the company can meet its immediate obligations without needing to access capital markets under potentially unfavorable conditions.
The company's ability to maintain a current ratio above 2.0 provides a necessary cushion against the lumpy revenue recognition inherent in its enterprise hospital contracts. This liquidity profile appears to be a key defensive feature, allowing management to continue its dividend policy despite the observed volatility in free cash flow.
Investors frequently misapply the reported 0.56 Debt/Equity ratio as a sign of extreme financial health, yet this metric likely obscures significant off-balance-sheet liabilities and pension obligations that are common in large-cap industrial healthcare firms, warranting a more comprehensive look at total leverage beyond simple headline figures.
Relying solely on the D/E ratio may lead to an underestimation of the company's true financial obligations and interest coverage risks. A more accurate assessment of Medtronic's leverage would require adjusting for lease liabilities and long-term pension commitments, which are not fully captured in the standard debt-to-equity calculation.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MDT stock.
Medtronic plc's current P/E ratio is 22.5x. The historical average is 32.6x. This places it at the 27th percentile of its historical range.
Medtronic plc's current EV/EBITDA is 14.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 17.8x.
Medtronic plc's return on equity (ROE) is 9.8%. The historical average is 16.6%.
Based on historical data, Medtronic plc is trading at a P/E of 22.5x. This is at the 27th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Medtronic plc's current dividend yield is 3.37% with a payout ratio of 75.8%.
Medtronic plc has 65.0% gross margin and 17.8% operating margin. Operating margin between 10-20% is typical for established companies.
Medtronic plc's Debt/EBITDA ratio is 3.0x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.